Comparing the current results to its competitors, Personalis Inc reported Revenue decrease in the 1 quarter 2026 year on year by -24.91 %, despite the revenue increase by the most of its competitors of 14.83 %, recorded in the same quarter.
Personalis Inc 's Comment on Competition and Industry Peers
The company operates in competitive markets with both established competitors and new entrants. It has a Commercialization and Reference Laboratory Agreement with Tempus AI, Inc. Additionally, the company conducts business with the U.S. Department of Veterans Affairs' Million Veteran Program, ModernaTX, Inc., and Merck & Co., Inc. Competitors identified in company filings include Merck & Co., Inc., ModernaTX, Inc., and Tempus AI, Inc.
November 10, 2025
In a landmark development for breast cancer patients and the realm of precision oncology, Personalis, Inc. (Nasdaq: PSNL) has announced Medicare coverage for its ultrasensitive NeXT Personal test, designed for monitoring cancer recurrence. This announcement represents a significant advancement in cancer surveillance, particularly for Medicare beneficiaries diagnosed with stage II and III breast cancer, which includes key subtypes such as HR+/HE.This coverage opens the door for wider access to cutting-edge diagnostic tools that can aid oncologists and patients in detecting the early stages of cancer resurgence more effectively. The NeXT Personal test leverages advanced genomics to deliver heightened sensitivi...
December 19, 2024
Investments and Collaborations Propel Personalis Inc. into a New Strategic Era FREMONT, Calif. In a significant advance towards a burgeoning future, Personalis, Inc. (NASDAQ: PSNL), a key player in the biotechnology landscape, has announced pivotal agreements with pharmaceutical titans Merck and Moderna. These collaborations mark not just an infusion of capital and confidence but also a continued journey towards innovative breakthroughs within the biotechnology sector.Personalis has welcomed a significant investment from Merck, who are recognized as MSD outside the United States and Canada, a testament to the burgeoning synergy between these industry leaders. This investment acts as a catalyst for Personal...
June 13, 2024
Personalis, Inc., a pioneer in advanced genomics for cancer, is making significant strides in the field of precision oncology with its revolutionary NeXT Personal liquid biopsy assay. Recent announcements by the company highlight its commitment to improving cancer detection rates and monitoring cancer recurrence. Furthermore, a strategic collaboration with Tempus for commercialization efforts validates Personalis groundbreaking technology. This article will delve into the details of these advancements, unveiling the potential impact they may have on the future of cancer diagnostics and treatment.The Shift in ASCO Data Highlights Conference Call:Originally scheduled for Wednesday, June 19, 2024, Personalis h...
June 5, 2024
Integrating Personalis NeXT Test Delivers Cutting-Edge Advances in Early-Stage Breast Cancer Recurrence Detection and Immunotherapy MonitoringFremont, Calif. - Personalis, Inc. (Nasdaq: PSNL) unveiled groundbreaking data at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL, showcasing the remarkable capabilities of their NeXT Personal test. The comprehensive study underlined the test s outstanding detection rates and performance in early-stage breast cancer recurrence detection and immunotherapy monitoring. This liquid biopsy test falls within a novel category of ultra-sensitive diagnostics aimed at early cancer recurrence detection.The NeXT Personal test is revolutionizing t...
June 4, 2024
By FREMONT, Calif. Personalis, Inc. (Nasdaq: PSNL) has unveiled groundbreaking data demonstrating the efficacy of its NeXT Personal test at the American Society for Clinical Oncology (ASCO) annual meeting in Chicago, IL. The presentation highlighted the test’s remarkable performance in detecting early-stage breast cancer recurrence and monitoring immunotherapy.Personalis’ NeXT Personal test is being heralded as a breakthrough in the field of liquid biopsies, which are non-invasive tests designed to detect the presence of cancer cells or fragments of tumor DNA circulating in the blood. Unlike traditional biopsy methods, liquid biopsies offer a more patient-friendly approach, requiring only a blood samp...
Biodesix Inc is a biotechnology company that utilizes advanced diagnostics to develop personalized medicine solutions for improving patient outcomes. Their business model involves leveraging their proprietary blood-based tests and data analytics to assist healthcare providers in making informed treatment decisions. By partnering with pharmaceutical companies and healthcare institutions, Biodesix aims to commercialize their innovative solutions and drive adoption in the healthcare industry.
Caredx Inc is a precision medicine company with a business model focused on transplant diagnostics. They develop and commercialize non-invasive tests to identify and monitor organ transplant rejection. By offering innovative solutions and services in the transplant field, Caredx Inc aims to improve outcomes for patients and provide healthcare professionals with valuable information to guide treatment decisions.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Fortrea Holdings Inc is a company that operates through its subsidiaries in the business of software and technology services, providing innovative solutions and products to its clients. Its business model focuses on developing and delivering custom software applications, digital platforms, and consulting services to cater to the specific needs of various industries.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Sources:
Personalis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Personalis Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
